



News Release

Cougar Biotechnology Appoints Tom Malley to Board of Directors

Los Angeles, CA, July 2, 2007 – Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced the appointment of Thomas R. Malley to the Company's Board of Directors.

Mr. Malley brings to Cougar more than 16 years of financial management and securities industry experience with life sciences companies. He recently retired from Janus Capital Management, LLC, where he served as a portfolio manager and securities analyst since 1991. During his tenure at Janus, he concentrated on global biotechnology and pharmaceutical companies. Mr. Malley managed several health care focused funds including the Janus Global Life Sciences Fund, which he managed from its inception in December 1998 until his retirement in May 2007.

Dr. Arie S. Belldegrun, M.D., FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology, said, "We are extremely pleased to attract to our board someone with such a wealth of industry-specific knowledge, coupled with outstanding financial acumen. We are delighted that Tom has agreed to join us and we look forward to his counsel as we continue to execute on our business plan."

Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "Tom's extensive experience in all aspects of financial analysis, coupled with his insight into the unique challenges associated with a development stage biotechnology company, will prove to be a tremendous asset for Cougar as we move forward with the development of our clinical programs."

Mr. Malley also serves as a director of Avigenics Corporation, a privately held biotechnology company based in Athens, Georgia, which focuses on the development of biogenic pharmaceuticals. He graduated from Stanford University with a B.S. in Biology and is a Chartered Financial Analyst.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements related to benefits to be derived from Cougar's drug development programs, including the potential advantages of CB7630 and its potential for use in the treatment of CRPC and in second line hormone and chemotherapy treatment settings. Such statements involve risks and uncertainties that could cause Cougar's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization, including the uncertainty of whether results in testing of CB7630 will be predictive of results in later stages of development. For a discussion of these and other factors, please refer to Cougar's annual report on Form 10-KSB for the year ended December 31, 2006 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Cougar undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contacts:

Cougar Biotechnology, Inc. -- +1-310-943-8040
Alan H. Auerbach, Chief Executive Officer and President
ahauerbach@cougarbiotechnology.com
Mariann Ohanesian, Director of Investor Relations
mohanesian@cougarbiotechnology.com

Russo Partners, LLC
David Schull, +1-212-845-4271
David.schull@russopartnersllc.com
Andreas Marathovouniotis, +1-212-845-4253
Andreas.marathis@russopartners.com

###